The upcoming week promises to be quite eventful, featuring reporting from five of the FTSE 100’s top ten, as well as four of the major US tech conglomerates. In addition,
GSK’s shares have opened higher after sales and profits for the first quarter exceeded expectations.
GSK’s shares rose at the opening of trading after the company reported that its Q1 revenue and profits had exceeded expectations, driven by the success of its Shingrix shingles vaccine.
Traders Cafe with Zak Mir: Bulletin Board Heroes, Wednesday 14th September 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Bitcoin, Audioboom, Caerus, Cloudbreak,
£400m Life Sciences hub in Stevenage To Be Built By GSK creating up to 5000 jobs
GSK, the pharmaceutical giant, plans to open a PS400m science hub at Stevenage. This could lead to up to 5,000 new jobs. Work is expected to start in 2022.
Novavax plans to ship COVID-19 vaccines to Europe from late 2021 – EU source
Novavax (NVAX.O) has told the European Union it plans to begin delivering its COVID-19 vaccine to the bloc towards the end of this year, new guidance that could lead to
Shard Capital: Insights into the small pharmaceutical company sector (video)
Wealth Manager at Shard Capital Stockbrokers, Simon Niven, provides some insights into the small pharmaceutical company sector.
GlaxoSmithKline plc (LSE/NYSE:GSK) Trelegy Ellipta: positive opinion from CHMP Europe
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion